EP0409654A2 - Mittel zur Verbesserung der Leberfunktion - Google Patents

Mittel zur Verbesserung der Leberfunktion Download PDF

Info

Publication number
EP0409654A2
EP0409654A2 EP90307978A EP90307978A EP0409654A2 EP 0409654 A2 EP0409654 A2 EP 0409654A2 EP 90307978 A EP90307978 A EP 90307978A EP 90307978 A EP90307978 A EP 90307978A EP 0409654 A2 EP0409654 A2 EP 0409654A2
Authority
EP
European Patent Office
Prior art keywords
dioxabicyclo
compound
octane
sesamin
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP90307978A
Other languages
English (en)
French (fr)
Other versions
EP0409654A3 (en
EP0409654B1 (de
Inventor
Yoshifumi Shinmen
Kengo Akimoto
Sumio Asami
Yoshihide Suwa
Yoshinori Kitagawa
Michihiro Sugano
Hideaki Yamada
Sakayu Shimizu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP1187497A external-priority patent/JP3001589B2/ja
Application filed by Suntory Ltd filed Critical Suntory Ltd
Priority to EP97112930A priority Critical patent/EP0826369B1/de
Priority to EP97112931A priority patent/EP0818196B1/de
Priority to DK97112930T priority patent/DK0826369T3/da
Priority to DK97112931T priority patent/DK0818196T3/da
Publication of EP0409654A2 publication Critical patent/EP0409654A2/de
Publication of EP0409654A3 publication Critical patent/EP0409654A3/en
Application granted granted Critical
Publication of EP0409654B1 publication Critical patent/EP0409654B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A23D7/0056—Spread compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/60—Salad dressings; Mayonnaise; Ketchup
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a liver function improver comprising, as an effective ingredient, dioxabicyclo[3.3.0]octane derivative, and to a food or drink containing this derivative having a liver function-improving action, a cholesterol level-­reducing action, and/or a neutral fat level-reducing action.
  • the liver is the largest substantial organ of a human body, in addition to the brain, and has various functions such as a detoxifying action, carbohydrate metabolism, protein metabolism, the formation and secretion of bile, the formation of blood coagulation factors, hormone-controlling action, and the action of storing various living body constituents such as fat, glycogen, proteins, and vitamins.
  • liver disorder caused by alcohol there has been adopted not only a method of controlling an intake of meat fat and an excessive intake of alcohol, but also a medicinal therapy using antihistamic agents, barbituric acid salts, adenosine triphosphate (ATP), pyrazole, a mixture of dihydroxy acetone and riboflavin, glucronic acid, arginine hydrochloride, and amino acid preparations such as glutathione. Nevertheless, the effects of these drugs are not satisfactory, and there is no certain remedial method other than a control of an excessive intake of alcohol.
  • antihistamic agents barbituric acid salts
  • ATP adenosine triphosphate
  • pyrazole a mixture of dihydroxy acetone and riboflavin
  • glucronic acid glucronic acid
  • arginine hydrochloride arginine hydrochloride
  • amino acid preparations such as glutathione
  • glutathione reduces or extinguishes an active oxygen species or free radical by glutathione peroxidase, or glutathione reacts with a poison through glutathione-­S-tranferase and discharges the poison from cells in the form of a glutathione conjugate, to exert the intended function whereby antioxidation, detoxification and a protection from radiation damage can be achieved.
  • glutamine per se is administered, the half-life is short (only several minutes) and tissue glutathione is not effectively increased. Accordingly, the development of glutathione derivatives and the like is now under investigation.
  • a primary task addressed herein is to provide a novel liver function improver and a food having a liver function-improving action.
  • liver-derived enzyme activity [glutamic-oxaloacetic aminotransferase (GOT) and glutamic-pyruvic aminotransferase (GPT)] in sera of mouse and rat is increased by liver disorder
  • GOT glutamic-oxaloacetic aminotransferase
  • GPT glutamic-pyruvic aminotransferase
  • the inventors searched for a liver function improver by using GOT and GPT as indications, and as a result, found that dioxabicyclo-­[3.3.0]octane isolated from sesame seeds, sesame lees, and sesame oil, or a synthesized dioxabicyclo-­[3.3.0]octane derivative, has a liver function-improving action, a cholesterol level-reducing and a neutral fat level-reducing action, and is very safe.
  • a liver function improver comprising, as an effective ingredient, a dioxabicyclo-­[3.3.0]octane derivative represented by the following general formula (1): wherein R1, R2, R3, R4, R5, and R6 independently represent a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, or R1 and R2 and/or R4 and R5 together form a methylene group or an ethylene group, and n, m and l are 0 or 1.
  • sesamin, sesaminol, episesamin, episesaminol, sesamolin, 2-(3,4-methylenedioxyphenyl)-­6-(3-methoxy-4-hydroxyphenyl)-3,7-dioxabicyclo-­[3.3.0]octane, 2,6-bis-(3-methoxy4-hydroxyphenyl)-­3,7-dioxabicyclo[3.3.0]octane or 2-(3,4-methylene­dioxyphenyl)-6-(3-methoxy-4-hydroxyphenoxy)-3,7-­dioxabicyclo[3.3.0]octane may be used. These derivatives may be used alone or in the form of a mixture of two or more thereof.
  • an extract composed mainly of the compound(s) may be obtained according to the following procedures.
  • an extract composed mainly of the relevant compound(s) may be obtained from sesame oil according to a method comprising extracting sesame oil with an organic solvent substantially immiscible with sesame oil and capable of extracting and dissolving the compound for the present invention, and concentrating the extract.
  • the organic solvent there can be mentioned, for example, acetone, methylethylketone, diethylketone, methanol and ethanol.
  • an extract composed mainly of the compound forthe present invention can be obtained by mixing sesame oil homogeneously with an organic solvent as mentioned above, allowing the mixture to stand at a low temperature, carrying out a phase separation according to a customary process, and removing the solvent from the solvent fraction by evaporation. More specifically, sesame oil is dissolved in 2 to 10 volumes, preferably 6 to 8 volumes of acetone, and the solution is allowed to stand at -80°C overnight. As a result, the oil component is precipitated, and the organic solvent is removed from the obtained filtrate by distillation, whereby an extract composed mainly of the compound of the present invention is obtained.
  • sesame oil is mixed with hot methanol or hot ethanol, the mixture is allowed to stand at room temperature, and the solvent is removed from the solvent fraction to obtain an extract composed mainly of the compound of the present invention. More specifically, sesame oil is mixed with hot methanol (higher than 50°C) or hot ethanol (higher than 50°) in a volume 2 to 10 times, preferably 5 to 7 times, as large as the volume of the sesame oil to effect a violent extraction.
  • the phase separation is effected by a phase separation when standing at room temperature or a centrifugal separation according to customary procedures, and the solvent is removed from the solvent fraction by distillation to obtain an extract composed mainly of the compound desired.
  • a supercritical gas extraction may be utilized.
  • the compound for the present invention can be obtained from an extract as mentioned above by treating the extract by a customary method such as column chromatography, high performance liquid chromatography, recrystallization, distillation, or liquid-liquid countercurrent distribution chroma­tography. More specifically, by using a reversed phase column (5C18) and methanol/water (60/40) as the eluent, the extract is subjected to high performance liquid chromatography, the solvent is removed by distillation, and the obtained crystal is recrystallized from ethanol to obtain the compound usable in the present invention, such as sesamin, episesamin, sesaminol or episesaminol. Sesame oil for use in the present invention can be either a purified product or a crude product.
  • a customary method such as column chromatography, high performance liquid chromatography, recrystallization, distillation, or liquid-liquid countercurrent distribution chroma­tography. More specifically, by using a reversed phase column (5C18) and methanol/
  • sesame seeds or sesame lees may be used.
  • sesame seeds or sesame lees are pulverized if necessary, and then subjected to the extraction according to customary procedures using an any solvent, for example, a solvent as mentioned above with respect to the extraction from sesame oil.
  • the extraction residue is separated, and the solvent is removed from the extract by evaporation or the like to obtain an extraction product.
  • the compound used in the present invention for example, sesamin, sesaminol, episesamin, episesaminol, sesamolin, 2-(3,4-methylene-­dioxyphenyl)-6-(3-methoxy-4-hydroxyphenyl)-3,7-­dioxabicyclo[3.3.0]octane, 2,6-bis-(3-methoxy-4-­hydroxyphenyl)-3,7-dioxabicyclo[3.3.0]octane or 2-(3,4-methylenedioxyphenyl)-6-(3-methoxy-4-hydroxyphen­oxy)-3,7-dioxabicyclo[3.3.0]octane, may be obtained from a sesame seed extract, a sesame lee extract or a crude sesame oil extract according to the same procedures as described above. Moreover, the compound used in the present invention may be obtained from a by-product formed in the sesame oil-preparing process.
  • the process for the purification of the compound and the process for obtaining the extract are not limited to those mentioned above, and the compound used in the present invention and the extract composed mainly of the compound of the present invention are not limited to those obtained from sesame oil, sesame lees and sesame seeds, but as is apparent to persons with ordinary skill in the art, all natural substances containing the compound used in the present invention can be used.
  • the compound used in the present invention and the extract composed mainly of the compound of the present invention are not limited to those obtained from sesame oil, sesame lees and sesame seeds, but as is apparent to persons with ordinary skill in the art, all natural substances containing the compound used in the present invention can be used.
  • Acanthopanax sessiliflorus paulowina
  • Ginkgo-biolobu and Piper lonum there can be mentioned Acanthopanax sessiliflorus , paulowina, Ginkgo-biolobu and Piper lonum.
  • sesamin and episesamin can be synthesized according to the process of Beroza et al. [J. Am. Chem. Soc., 78 , 1242 (1956)].
  • Pinoresinol in the general formula (I), R1 and R4 represent H, R2 and R5 represent CH3 , and n, m and l are zero] can be synthesized according to the process of Freundenberg et al. [Chem. Ber., 86 , 1157 (1953)].
  • syringaresinol in the general formula (I), R1 and R4 represent H, R2, R3, R3, R5 and R6 represents CH3 , n is zero, and each of m and l is 1) can be synthesized according to the process of Freundenberg et al [Chem. Ber., 88 , 16 (1955)].
  • the compound used in the present invention also may be used in the form of a glycoside. Furthermore, compounds used in the present invention can be used alone or in combination with other liver function improver or a functional factor of a food.
  • the liver function improver of the present invention may be orally administered, or non-orally administered, for example, by intramuscular injection, hypodermic injection or intravenous injection.
  • the dosage depends on the state of a person to whom the liver function improver is administered, but in general, in the case of the oral administration, the dosage is 1 to 100 mg/day, and in the case of the non-oral administration, the dosage is 0.1 to 20 mg/day.
  • a solubilizing agent for a drug for example, a nonionic surface active agent
  • the compound may for example be dissolved under heating in a nonionic surface active agent such as POE(60) hardened castor oil or POE sorbitan-monooleate in a volume 80 times as large as the volume of the compound of the present invention, and the solution is diluted with a physiological saline to form an injection solution.
  • An isotonic agent, a stabilizer, an antiseptic agent, and an alagesic agent can be incorporated according to need. If necessary, the compound of the present invention may be formed into an emulsion, a capsule, a dust, a granule or a tablet.
  • the compound of the present invention into foods containing oil and fat, although the kind of food into which the compound of the present invention is incorporated is not limited.
  • natural foods such as meat, fish and nut, foods to which oil and fat are added at the cooking step, such as Chinese meals, Chinese noodles and soups, foods cooked by using oil and fat as the heating medium, such as Japanese fried foods, fried bean curd, Chinese fried rice, doughnuts and fried dough cakes, oil and fat foods or processed foods to which oil and fat are added at the processing step, such as butter, margarine, mayonnaise, dressings, chocolate, instant noodles, caramels, biscuits and ice creams, and foods onto which oil and fat are sprayed or coated at the processing step, such as sliced and dried rice cakes, hard biscuits and bean-jam buns.
  • an extract composed mainly of the compound of the present invention may have effective ingredients inherently contained in an edible oil and fat or extracts thereof, addition of this extract of the present invention can be easily accomplished and the extract of the present invention can easily added to the above-mentioned foods.
  • the foods are not limited to oil- or and fat-containing foods, and the extract of the present invention can be added to all foods to provide foods having a liver function-improving action, a cholesterol level-reducing action, and a neutral fat level-reducing action.
  • the amount of the compound of the present invention is not particularly critical, but preferably the amount of the compound of the present invention is 0.001 to 20% by weight, especially 0.01 to 10.0% by weight, based on the food to which the compound of the present invention is added. If the amount of the compound of the present invention is smaller than 0.001% by weight, the effect is low, and if the amount is larger than 20% by weight, the taste and flavor of some foods are adversely affected. Preferably, the content of the compound in an extract is at least 25%. Moreover, the compound of the present invention may be converted to a cyclodextrin inclusion compound and the formed powder can be used.
  • Butter is a very popular food prepared from butter fat or cream, a milk solid and a natural colorant, and further, contains sodium chloride.
  • the fat content in butter is usually about 80%.
  • cream obtained by centrifugal separation is subjected to stirring (churning) directly or after lactic acid fermentation, whereby the fat globule membrane is destroyed and fat is fused into particles, and sodium chloride is added to the churned cream and kneading (working) is carried out to obtain a product having a homogeneous texture.
  • the thus-prepared butter is a popular food because of its peculiar and characteristic taste and flavor, but since butter has a very high cholesterol content (the cholesterol level is about 220 mg/100 g), health experts recommend eliminating butter from a food or reducing the content of butter for lowering or controlling the intake of cholesterol. If a compound, or an extract composed mainly of the compound of the present invention is added to butter, an effect of preventing the increase of the cholesterol level after the intake of butter can be obtained. Moreover, since the product of the present invention is not an imitation food, the inherent taste and flavor of butter can be retained.
  • the compound of the present invention or the extract composed mainly of the compound of the present invention can be added at any step of the butter-­preparing process, but the addition at the kneading operation (working) is especially preferable.
  • Mayonnaise is prepared by mixing edible oil with vinegar by using egg yolk lecithin as an emulsifier, and sugar, table salt, mustard and white pepper are used as additives.
  • Mayonnaise and dressings are o/w type emulsions in which the water layer is a main component, and according to JAS standards, mayonnaise is defined as a product having an oil content, which is formed by using an egg as the emulsifier, and dressings are divided into a salad dressing having an oil content of at least 65%, for which an emulsifier other than an egg can be used, and a French dressing formed without using egg.
  • a problem resides in the use of the egg yolk as the emulsifier.
  • the effect of the compound of the present invention or the extract composed mainly of the compound of the present invention as the functional factor may be increased by a combined use thereof with other substances, and the combined use of a fatty acid having 16 to 20 carbon atoms and 1 to 3 double bonds in the carbon chain, especially ⁇ -linolenic acid (6,9,12-octadecatrienoic acid) or dihomo- ⁇ -linolenic acid (8,11,14-eicosatrienoic acid), is preferred.
  • the acid can be used directly or in the form a salt of sodium, potassium or ammonium or an ester such as a methyl ester or an ethyl ester.
  • oils and fats containing these fatty acids can be used.
  • an antiinflammatory action an anti-­thrombosis action, and a hypotensive action
  • the compound of the present invention and the extract composed mainly of the compound of the present invention can be used as a remedy for related diseases, such as inflammatory diseases, heartvascular and thrombotic diseases, mental diseases, chest and prostate diseases, diabetes, endometritis, malnutrition, menstrual disorders, and malignant tumors.
  • related diseases such as inflammatory diseases, heartvascular and thrombotic diseases, mental diseases, chest and prostate diseases, diabetes, endometritis, malnutrition, menstrual disorders, and malignant tumors.
  • the anti-thrombosis action the antiinflammatory action
  • the hypotensive action can be significantly enhanced by the effect derived from prostaglandin I by the combined use with ⁇ -linolenic acid and dihomo- ⁇ -­linolenic acid.
  • the compound of the present invention has a very high activity; this is made obvious from the fact that, even if sesamin was continuously administered (oral administration) to 7-weeks-old ICR male mice at a dosage of 2.14 g/day/kg continuously for two weeks, no abnormal symptoms were observed.
  • the extract was dissolved in 3.2 l of acetone, the solution was allowed to stand at -80°C overnight, and the organic solvent was removed by distillation from the filtrate obtained by the filtration to obtain 103 g of an extract composed mainly of the compounds.
  • the substance was analyzed, it was found to comprise 19.6% of sesamin, 30.6% of episesamin and 10.2% of sesaminol and episesaminol based on the extract, and the content of the compound in the extract was 60.4%.
  • mice Eight-weeks-old male mice (CD-1 mice supplied by Nippon Charles River) were raised for one week with an ordinary feed (CE-2 feed supplied by Nippon Clea). The mice were then divided into 4 groups, each consisting of 10 mice, and the mice of one group were raised with the same ordinary feed, and the mice of the other three groups ware raised with a high cholesterol feed having 1% of cholesterol, 0.2% of cholic acid and 5% of olive oil incorporated therein. Of the three groups to which the high-cholesterol feed was given, the two groups were raised with a feed obtained by incorporating 0.4 or 0.6% of the above-mentioned extract into the high-­cholesterol feed. After two weeks' growth, the mice were fasted for 15 hours and blood was collected.
  • mice were raised for one week with the ordinary feed, and the mice were divided into four groups, each consisting of 10 mice.
  • the mice of one group were raised with the same ordinary feed, and the mice of the remaining three groups were raised with a high-cholesterol feed formed by adding 1% of cholesterol, 0.2% of cholic acid and 5% of evening primrose oil to the ordinary feed.
  • a feed formed by adding 0.4 to 0.6% of a purified mixture comprising 61.5% of sesamin and 38.0% of episesamin to the high-cholesterol feed was given to the mice of the two groups among the three groups to which the high-­cholesterol feed was given. After two weeks' growth, the mice were fasted for 15 hours and blood was collected.
  • a feed formed by adding 1.0 or 2.0% of the mixture of sesamin and episesamin used in Example 2 to the above-mentioned high-cholesterol feed was given to the rats of two groups among the three groups to which the high-cholesterol feed was given. After 1 week's growth, blood was partially collected, and after two weeks' growth, blood was wholly collected. Each blood collection was effected after 17 hours' fasting. The GOT and GPT activities in the serum were measured. The results are shown in Table 3, and from these results, it is seen that the increase of GOT by the high-cholesterol feed was controlled by using the mixture of sesamin and episesamin.
  • mice Nine-weeks-old male CDF-1 mice (supplied by Nippon Clea) were raised for 1 week, and the mice were divided into three groups, each consisting of 7 mice. The mice of two groups other than the control group were raised in a chamber filled with air containing 12 ppm of ethanol. After 1 week's growth, the mice were fasted for 16 hours, and blood was collected. The total cholesterol (T-CHO) content, the triglyceride (TG) content, the GOT and GPT activities and the total bilirubin content in the serum were measured, and the results are shown in Table 4.
  • T-CHO total cholesterol
  • TG triglyceride
  • GOT and GPT activities The total bilirubin content in the serum were measured, and the results are shown in Table 4.
  • mice Eight-weeks-old male CDF-1 mice (supplied by Nippon Clea) were raised for 1 week and were divided into three groups, each consisting of 7 mice. To two groups other than the control group, 1 mg/kg of carbon tetrachloride was administered in the abdominal cavity. To one of these two groups, simultaneously, 100 mg/kg of sesamin was forcibly orally administered. Then the mice were fasted for 16 hours and blood was collected. The total cholesterol (T-CHO), the triglyceride (TG) content, GOT, GPT and the total bilirubin content in the serum were measured. The results are shown in Table 5.
  • mice of the Wister line were divided into two groups (control group and sesamin group), each consisting of 6 rats.
  • the rats of the control group were raised for 22 days with a basic feed and the rats of the sesamin group were raised for 22 days with a feed formed by adding 0.5% of sesamin to the basic feed.
  • the rats were fasted overnight, and 1 g/kg of ethanol (20%) was forcibly orally administered. After 1 and 3 hours, blood was collected from the tail vein and the alcohol concentration in blood was measured. After 1 hour from the point of the administration, the ethanol concentration was 0.5 mg/ml in the control group but the ethanol concentration was 0.27 mg/ml in the sesamin group.
  • the ethanol concentration was 0.12 mg/ml in the control group but the ethanol concentration was 0.02 mg/ml in the sesamin group. Accordingly, it was confirmed that ethanol disappeared more quickly in the sesamin group than in the control group.
  • a nonionic surface active agent (TO-10M supplied by Nikko Chemicals) was dissolved 2.5 g of the compound under heating at 122°C Then, 4.8985 g of a sterilized physiological saline solution was added to the solution and the mixture was thoroughly stirred. The liquid was sterilely distributed into vials, and the vials were sealed to obtain injections.
  • Example 2 In 180 ml of salad oil was dissolved 0.9 g of the extract composed mainly of the compound, which was obtained in Example 1. Separately, a vessel was charged with one egg yolk, 3 g of table salt, 1 g of mustard, sugar, a spice and a chemical seasoning, and 3 ml of vinegar was added into the vessel and the mixture was strongly stirred by a whip to form a mayonnaise base. Then, 12 ml of vinegar and 180 ml of the salad oil containing the compound dissolved therein were added to the mayonnaise base with stirring to obtain a mayonnaise containing the compound of the present invention.
  • Example 9 Four-weeks-old male rats of the SD line were raised for 3 weeks with a feed containing 10% of the butter which was obtained in Example 9 (compound-added group), or a butter not containing the compound of the present invention (compound-free group). After 3 weeks, the body weight, the liver weight, the plasma cholesterol content, the plasma triglyceride content and the plasma phospholipid content were measured. The results are shown in Table 6.
  • ⁇ 5-desaturase inhibitors i.e., sesamin, episesamin, sesaminol and episesaminol, were obtained according to the method described in European Application 90302374.5.
  • Sesamine-containing mayonnaise and sesamin-containing butter were prepared in the same manner as described in Examples 7 and 8 by using 0.54 g and 1.2 g of sesamin, respectively. Similarly, foods containing the compounds, singly or in combination were obtained. The compound as used was a colorless (white) crystal and had no taste or smell. Accordingly, the compound did not have any influence on the inherent quality of the foods.
  • a sesamin-containing juice was prepared by adding 1 g of the obtained powder to 100 ml of a juice.
  • Example 13 The procedures of Example 13 were repeated by using the compound and the extract embodying the present invention. Juices containing the compound of the present invention and the extract, respectively, were obtained.
  • a starting oil and fat material comprising 30% of edible hardened soybean oil, 10% of edible hardened cotton seed oil, 40% of soybean salad oil, 10% of palm oil and 10% of corn oil, 1 g of sesamin was incorporated and dissolved. Then, 15 g of water, 1.2 g of table salt, 0.3 g of monoglyceride, 0.1 g of lecithin, a trace of carotene, 0.00001 g of a flavor and 1.4 g of a milk solid were added to the solution, and the mixture was emulsified, rapidly cooled, and kneaded to obtain a sesamin-containing margarin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Finger-Pressure Massage (AREA)
  • Fats And Perfumes (AREA)
EP90307978A 1989-07-21 1990-07-20 Mittel zur Verbesserung der Leberfunktion Expired - Lifetime EP0409654B1 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP97112930A EP0826369B1 (de) 1989-07-21 1990-07-20 Therapeutische Anwendung von Dioxabicyclo(3.3.0)oktan-Verbindungen
EP97112931A EP0818196B1 (de) 1989-07-21 1990-07-20 Kapsel, enthaltend ein Dioxabicyclo(3.3.0)oktan
DK97112930T DK0826369T3 (da) 1989-07-21 1990-07-20 Terapeutisk anvendelse af dioxabicyclo[3,3,0]octanforbindelser
DK97112931T DK0818196T3 (da) 1989-07-21 1990-07-20 Kapsel, der indeholder dioxabicyclo[3.3.0]octan-forbindelser

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP1187497A JP3001589B2 (ja) 1989-07-21 1989-07-21 リグナン類含有飲食物
JP18749789 1989-07-21
JP187497/89 1989-07-21
JP8750090 1990-04-03
JP87500/90 1990-04-03
JP8750090 1990-04-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP97112931A Division EP0818196B1 (de) 1989-07-21 1990-07-20 Kapsel, enthaltend ein Dioxabicyclo(3.3.0)oktan
EP97112930A Division EP0826369B1 (de) 1989-07-21 1990-07-20 Therapeutische Anwendung von Dioxabicyclo(3.3.0)oktan-Verbindungen

Publications (3)

Publication Number Publication Date
EP0409654A2 true EP0409654A2 (de) 1991-01-23
EP0409654A3 EP0409654A3 (en) 1992-05-27
EP0409654B1 EP0409654B1 (de) 2001-11-07

Family

ID=26428763

Family Applications (3)

Application Number Title Priority Date Filing Date
EP97112930A Expired - Lifetime EP0826369B1 (de) 1989-07-21 1990-07-20 Therapeutische Anwendung von Dioxabicyclo(3.3.0)oktan-Verbindungen
EP90307978A Expired - Lifetime EP0409654B1 (de) 1989-07-21 1990-07-20 Mittel zur Verbesserung der Leberfunktion
EP97112931A Expired - Lifetime EP0818196B1 (de) 1989-07-21 1990-07-20 Kapsel, enthaltend ein Dioxabicyclo(3.3.0)oktan

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP97112930A Expired - Lifetime EP0826369B1 (de) 1989-07-21 1990-07-20 Therapeutische Anwendung von Dioxabicyclo(3.3.0)oktan-Verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP97112931A Expired - Lifetime EP0818196B1 (de) 1989-07-21 1990-07-20 Kapsel, enthaltend ein Dioxabicyclo(3.3.0)oktan

Country Status (8)

Country Link
US (1) US5180588A (de)
EP (3) EP0826369B1 (de)
AT (3) ATE285765T1 (de)
CA (2) CA2021714C (de)
DE (3) DE69034084T2 (de)
DK (3) DK0409654T3 (de)
ES (3) ES2195058T3 (de)
SG (1) SG42967A1 (de)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0488513A2 (de) * 1990-10-22 1992-06-03 Suntory Limited Verwendung von Dioxabicyclo [3.3.0]octane Derivaten zur Herstellung eines Arzneimittels zur Hemmung des Cholesterinmetabolismus.
EP0519673A1 (de) * 1991-06-15 1992-12-23 Suntory Limited Arzneizusammensetzung auf Basis von Dioxabicyclo[3.3.0]octanderivaten
WO1995022971A1 (en) * 1994-02-25 1995-08-31 New England Deaconess Hospital Corporation Anti-inflammatory and infection protective effects of sesamin-based lignans
EP0681788A2 (de) * 1994-05-12 1995-11-15 Suntory Limited Dioxabicyclo 3.3.0 octan-Derivate, z.B. Sesamin etc., zur Vorbeugung und Erleichterung von Allergiesymptomen
EP0729753A1 (de) * 1995-02-01 1996-09-04 Suntory Limited Mittel für Behandlung und Verhütung von Hypertonie und damit zusammenhängenden Krankheitssymptomen und Erkrankungen, ihre Herstellung und Verwendung
EP0782827A1 (de) * 1995-07-04 1997-07-09 Suntory Limited Nahrungsmittelzusammensetzung mit einem ausgleichenden zusatz für omega-6 und omega-3 ungesättigte fettsäuren
EP1864659A1 (de) * 2005-03-31 2007-12-12 Suntory Limited Eine lignanverbindung enthaltende öl-in-wasser-emulsion und diese enthaltende zusammensetzung
US7943663B2 (en) 2005-09-30 2011-05-17 Suntory Holdings Limited Process and an apparatus for producing episesamin-rich compositions
US9408803B2 (en) 2006-03-31 2016-08-09 Suntory Holdings Limited Compositions containing lignan-class compounds

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020031563A1 (en) * 1992-09-30 2002-03-14 Hodge Thomas W. Method of inhibiting tumor necrosis factor
US5397778A (en) * 1994-02-25 1995-03-14 New England Deaconess Hospital Corporation Enteral formulations for treatment of inflammation and infection
FR2738828B1 (fr) * 1995-09-20 1997-10-17 Commissariat Energie Atomique Utilisation de cyclodextrines naturelles et de leurs derives pour la solubilisation d'agents anti-agregants plaquettaires de la famille des ginkgolides
AU7068896A (en) * 1995-11-09 1997-05-15 Corunum Corporation Protein composition derived from sesame seed and use thereof
US5811313A (en) * 1997-06-17 1998-09-22 King Pharmaceuticals, Inc. Identification test for highly refined sesame oil
US20030091553A1 (en) * 2001-10-19 2003-05-15 Gehlsen Kurt R. Use of histamine to treat liver disease
JP4388248B2 (ja) * 2001-10-29 2009-12-24 株式会社日立製作所 最適ポートフォリオ決定方法および装置
FI114917B (fi) * 2002-08-29 2005-01-31 Hormos Nutraceutical Oy Ltd Lignaanikomplekseja
CA2592532C (en) * 2004-12-28 2015-02-17 Suntory Limited Sesamin/episesamin compositions with improved bioavailability
JP5069416B2 (ja) * 2006-03-15 2012-11-07 サントリーホールディングス株式会社 吸湿性の改善された飲食品用組成物
US20090054443A1 (en) 2006-03-15 2009-02-26 Suntory Limited Compositions containing riboflavin and sesamin-class compounds
CA2680751C (en) * 2007-03-15 2016-01-26 Suntory Holdings Limited Use of dioxabicyclo[3.3.0]octane derivatives as anti-fatigue agents
KR101528380B1 (ko) * 2007-09-19 2015-06-11 산토리 홀딩스 가부시키가이샤 세사민류와 아라키돈산류를 함유하는 조성물
AU2008301699B2 (en) * 2007-09-19 2014-10-02 Suntory Holdings Limited Composition Comprising Sesamin Component and Vitamin B1 Component
JP6156795B2 (ja) * 2013-07-05 2017-07-05 公立大学法人大阪市立大学 脂肪細胞分化の抑制用、脂肪細胞の脂肪蓄積量低減用および／または脂肪細胞のアディポネクチン分泌促進用組成物
CN104804012B (zh) * 2015-04-24 2017-06-30 沈阳药科大学 一种具有抗耐药菌活性的化合物止泻木脂素a及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427694A (en) * 1982-06-11 1984-01-24 The Vinoxen Company, Inc. Sesamin as a psychotropic agent
EP0269754B1 (de) * 1986-06-13 1993-11-03 TSUMURA & CO. Biphenylabkömmlinge, verfahren zur herstellung und verwendung
JPH01135892A (ja) * 1987-11-20 1989-05-29 Kuki Sangyo Kk 抗酸化性物質の製造方法
US4868207A (en) * 1988-07-28 1989-09-19 Taisho Pharmaceutical Co., Ltd. Bis (methylenedioxy) biphenyl compounds useful for the treatment of liver diseases
JP3070611B2 (ja) * 1989-03-07 2000-07-31 サントリー株式会社 △▲上５▼―不飽和化酵素阻害剤
JPH02255616A (ja) * 1989-03-27 1990-10-16 Rooman Kogyo:Kk 肝臓疾患用剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BASIC LIFE SCIENCE, vol. 39, 1986, pages 131-142; M. NAMIKI et al.: "Antioxidants/antimutagens in foods", Introduction, pages 138-139. *
HIROSHIMA JOURNAL OF MEDICAL SCIENCES, vol. 34, no. 3, September 1985, pages 303-309, Hiroshima University School of Medicine, Hiroshima, JP; S. NAKAGAWA et al.: "Cytoprotective activity of components of garlic, ginseng and ciuwjia on hepatocyte injury induced by carbon tetrachloride in vitro", Introduction; chart 1; Discussion. *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0488513A3 (de) * 1990-10-22 1992-06-17 Suntory Limited Verwendung von Dioxabicyclo [3.3.0]octane Derivaten zur Herstellung eines Arzneimittels zur Hemmung des Cholesterinmetabolismus.
US5270335A (en) * 1990-10-22 1993-12-14 Suntory Limited Method of inhibiting metabolism of cholesterol
EP0488513A2 (de) * 1990-10-22 1992-06-03 Suntory Limited Verwendung von Dioxabicyclo [3.3.0]octane Derivaten zur Herstellung eines Arzneimittels zur Hemmung des Cholesterinmetabolismus.
US5637610A (en) * 1991-06-15 1997-06-10 Suntory Limited Composition containing dioxabicyclo [3.3.0] octane derivative
EP0519673A1 (de) * 1991-06-15 1992-12-23 Suntory Limited Arzneizusammensetzung auf Basis von Dioxabicyclo[3.3.0]octanderivaten
WO1995022971A1 (en) * 1994-02-25 1995-08-31 New England Deaconess Hospital Corporation Anti-inflammatory and infection protective effects of sesamin-based lignans
US5762935A (en) * 1994-02-25 1998-06-09 Beth Israel Deaconess Medical Center, Inc. Anti-inflammatory and infection protective effects of sesamin-based lignans
EP0681788A3 (de) * 1994-05-12 1998-01-14 Suntory Limited Dioxabicyclo 3.3.0 octan-Derivate, z.B. Sesamin etc., zur Vorbeugung und Erleichterung von Allergiesymptomen
AU703327B2 (en) * 1994-05-12 1999-03-25 Suntory Holdings Limited Agent for prevention or alleviation of allergy sypmtoms
EP0681788A2 (de) * 1994-05-12 1995-11-15 Suntory Limited Dioxabicyclo 3.3.0 octan-Derivate, z.B. Sesamin etc., zur Vorbeugung und Erleichterung von Allergiesymptomen
US5889046A (en) * 1995-02-01 1999-03-30 Suntory Limited Method for preventing or alleviating cerebral apoplexy
EP0729753A1 (de) * 1995-02-01 1996-09-04 Suntory Limited Mittel für Behandlung und Verhütung von Hypertonie und damit zusammenhängenden Krankheitssymptomen und Erkrankungen, ihre Herstellung und Verwendung
US5948451A (en) * 1995-07-04 1999-09-07 Suntory Limited Method of modifying the balance of omega unsaturated fatty acids using a dioxabicyclo octane derivative
EP0782827A4 (de) * 1995-07-04 1997-08-20
EP0782827A1 (de) * 1995-07-04 1997-07-09 Suntory Limited Nahrungsmittelzusammensetzung mit einem ausgleichenden zusatz für omega-6 und omega-3 ungesättigte fettsäuren
US6159507A (en) * 1995-07-04 2000-12-12 Suntory Limited Food composition containing an omega-6/omega-3 unsaturated fatty acid balance modifier
CN1073825C (zh) * 1995-07-04 2001-10-31 三得利公司 二氧杂二环[3.3.0]辛烷衍生物的新用途
EP1864659A1 (de) * 2005-03-31 2007-12-12 Suntory Limited Eine lignanverbindung enthaltende öl-in-wasser-emulsion und diese enthaltende zusammensetzung
EP1864659A4 (de) * 2005-03-31 2009-08-12 Suntory Holdings Ltd Eine lignanverbindung enthaltende öl-in-wasser-emulsion und diese enthaltende zusammensetzung
CN101404995B (zh) * 2005-03-31 2013-07-31 三得利控股株式会社 含木脂素类化合物水包油滴型乳剂及含有其的组合物
US8685455B2 (en) 2005-03-31 2014-04-01 Suntory Holdings Limited Oil-in-water emulsions containing lignan-class compounds and compositions containing the same
US7943663B2 (en) 2005-09-30 2011-05-17 Suntory Holdings Limited Process and an apparatus for producing episesamin-rich compositions
US9408803B2 (en) 2006-03-31 2016-08-09 Suntory Holdings Limited Compositions containing lignan-class compounds

Also Published As

Publication number Publication date
DE69033848D1 (de) 2001-12-13
EP0409654A3 (en) 1992-05-27
EP0409654B1 (de) 2001-11-07
DE69034084D1 (de) 2003-07-10
DK0409654T3 (da) 2001-12-27
DE69033848T2 (de) 2002-04-04
ES2195058T3 (es) 2003-12-01
EP0826369A1 (de) 1998-03-04
DE69034084T2 (de) 2003-12-04
EP0826369B1 (de) 2003-06-04
DK0826369T3 (da) 2003-09-29
DE69034181T2 (de) 2006-01-26
US5180588A (en) 1993-01-19
CA2172855A1 (en) 1991-01-22
EP0818196A1 (de) 1998-01-14
CA2021714A1 (en) 1991-01-22
EP0818196B1 (de) 2004-12-29
DK0818196T3 (da) 2005-05-02
CA2172855C (en) 2000-02-15
ES2161680T3 (es) 2001-12-16
ATE285765T1 (de) 2005-01-15
ATE241978T1 (de) 2003-06-15
ES2235205T3 (es) 2005-07-01
CA2021714C (en) 1996-07-23
ATE208195T1 (de) 2001-11-15
DE69034181D1 (de) 2005-02-03
SG42967A1 (en) 1997-10-17

Similar Documents

Publication Publication Date Title
EP0826369B1 (de) Therapeutische Anwendung von Dioxabicyclo(3.3.0)oktan-Verbindungen
US5211953A (en) Liver function improver
JP3512196B2 (ja) オメガ６系・オメガ３系不飽和脂肪酸のバランス調節剤を配合してなる食品組成物
EP1307108B1 (de) Öl-/fett-zusammensetzung
US6852758B2 (en) Oil composition
RU2279226C2 (ru) СПОСОБ ПОЛУЧЕНИЯ МАСЛЯНОЙ И ЖИРОВОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ ГИДРОФОБНЫЕ КОМПОНЕНТЫ Glycyrrhiza, МАСЛЯНАЯ И ЖИРОВАЯ КОМПОЗИЦИЯ И МАСЛО- И ЖИРОСОДЕРЖАЩИЙ ПИЩЕВОЙ ПРОДУКТ
EP1211305B1 (de) Fettzusammensetzungen
EP0519673B1 (de) Arzneizusammensetzung auf Basis von Dioxabicyclo[3.3.0]octanderivaten
KR100399671B1 (ko) 고혈압증또는이에기인하는의학적증상의예방또는개선제
EP0488513B1 (de) Verwendung von Dioxabicyclo [3.3.0]octane Derivaten zur Herstellung eines Arzneimittels zur Hemmung des Cholesterinmetabolismus.
KR20040095263A (ko) 체온상승제
WO2005011672A1 (ja) 生活習慣病予防・改善用の油脂加工組成物
JP2001064672A (ja) 体脂肪燃焼促進剤
WO2004064830A1 (ja) 生活習慣病予防・改善用の油脂加工組成物
JP2006306855A (ja) 発癌抑制用油脂含有組成物
EP1864643A1 (de) Öl/fetthaltige zusammensetzung zur unterdrückung der entstehung von krebs
JPH0670715A (ja) マヨネーズ類の製造法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19920715

17Q First examination report despatched

Effective date: 19940719

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 208195

Country of ref document: AT

Date of ref document: 20011115

Kind code of ref document: T

XX Miscellaneous (additional remarks)

Free format text: TEILANMELDUNG 97112931.7 EINGEREICHT AM 28/07/97.

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

REF Corresponds to:

Ref document number: 69033848

Country of ref document: DE

Date of ref document: 20011213

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2161680

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

ET Fr: translation filed
REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20020400455

Country of ref document: GR

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: SUNTORY LIMITED

Free format text: SUNTORY LIMITED#1-40, DOJIMAHAMA 2-CHOME, KITA-KU#OSAKA-SHI, OSAKA 530-8203 (JP) -TRANSFER TO- SUNTORY LIMITED#1-40, DOJIMAHAMA 2-CHOME, KITA-KU#OSAKA-SHI, OSAKA 530-8203 (JP)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20090619

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20090710

Year of fee payment: 20

Ref country code: ES

Payment date: 20090804

Year of fee payment: 20

Ref country code: DK

Payment date: 20090714

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20090626

Year of fee payment: 20

Ref country code: LU

Payment date: 20090804

Year of fee payment: 20

Ref country code: CH

Payment date: 20090721

Year of fee payment: 20

Ref country code: DE

Payment date: 20090716

Year of fee payment: 20

Ref country code: GB

Payment date: 20090715

Year of fee payment: 20

Ref country code: NL

Payment date: 20090715

Year of fee payment: 20

Ref country code: AT

Payment date: 20090715

Year of fee payment: 20

Ref country code: SE

Payment date: 20090708

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20090716

Year of fee payment: 20

REG Reference to a national code

Ref country code: NL

Ref legal event code: V4

Effective date: 20100720

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

BE20 Be: patent expired

Owner name: *SUNTORY LTD

Effective date: 20100720

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20100719

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20100721

EUG Se: european patent has lapsed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100720

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100721

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100720